These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11802202)

  • 1. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma.
    Giannelli G; Bergamini C; Marinosci F; Fransvea E; Quaranta M; Lupo L; Schiraldi O; Antonaci S
    Int J Cancer; 2002 Feb; 97(4):425-31. PubMed ID: 11802202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization.
    Daniele A; Divella R; Quaranta M; Mattioli V; Casamassima P; Paradiso A; Garrisi VM; Gadaleta CD; Gadaleta-Caldarola G; Savino E; Maci R; Bellizzi A; Fazio V
    Clin Biochem; 2014 Feb; 47(3):184-90. PubMed ID: 24355694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
    Zhang S; Li L; Lin JY; Lin H
    World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential.
    Arii S; Mise M; Harada T; Furutani M; Ishigami S; Niwano M; Mizumoto M; Fukumoto M; Imamura M
    Hepatology; 1996 Aug; 24(2):316-22. PubMed ID: 8690399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
    Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
    Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.
    Bernardo MM; Fridman R
    Biochem J; 2003 Sep; 374(Pt 3):739-45. PubMed ID: 12755684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
    Kim JR; Kim CH
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.
    Lempinen M; Lyytinen I; Nordin A; Tervahartiala T; Mäkisalo H; Sorsa T; Isoniemi H
    Ann Med; 2013 Nov; 45(7):482-7. PubMed ID: 23962148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of glucose-regulated protein 78 decreases the invasion, metalloproteinase expression and ECM degradation in hepatocellular carcinoma cells.
    Li H; Song H; Luo J; Liang J; Zhao S; Su R
    J Exp Clin Cancer Res; 2012 Apr; 31(1):39. PubMed ID: 22546345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells.
    Chung TW; Moon SK; Lee YC; Kim JG; Ko JH; Kim CH
    Arch Biochem Biophys; 2002 Dec; 408(2):147-54. PubMed ID: 12464265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
    Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
    Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma.
    Yoshizaki T; Maruyama Y; Sato H; Furukawa M
    Int J Cancer; 2001 Jan; 95(1):44-50. PubMed ID: 11241310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma.
    Joo YE; Seo YH; Lee WS; Kim HS; Choi SK; Rew JS; Park CS; Kim SJ
    Korean J Intern Med; 2000 Dec; 15(3):171-8. PubMed ID: 11242804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor and matrix metalloproteinase-2 correlates with the invasion and metastasis of hepatocellular carcinoma.
    Liu Z; Yan L; Xiang T; Jiang L; Yang B
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):249-50, 254. PubMed ID: 12856590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.
    Groblewska M; Mroczko B; Gryko M; Pryczynicz A; Guzińska-Ustymowicz K; Kędra B; Kemona A; Szmitkowski M
    Tumour Biol; 2014 Apr; 35(4):3793-802. PubMed ID: 24395652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.